Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia

JAMA

Volumn 311, Issue 3, 2014, Pages 279-286

  Steele, Anna M ^a   Shields, Beverley M ^a   Wensley, Kirsty J ^a   Colclough, Kevin ^b   Ellard, Sian ^a,b   Hattersley, Andrew T ^a  

^a Exeter Medical School ^*  (United Kingdom)

^b ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIDIABETIC AGENT; GLUCOKINASE; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GCK GENE; GENE MUTATION; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; UNITED KINGDOM;

ADULT; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOKINASE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; MUTATION; PREVALENCE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84892649702     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.283980     Document Type: Article

References (32)

1. 1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968-983.
2. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.
3. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329(5):304-309.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
5. Nathan DM, Cleary PA, Backlund JY, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653.
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
7. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ. 2001;322(7277):15-18.
8. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care. 2011;34(suppl 1):S11-S61.
9. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
10. Sagen JV, Bjørkhaug L, Molnes J, et al. Diagnostic screening of MODY2/GCK mutations in the Norwegian MODY Registry. Pediatr Diabetes. 2008;9(5):442-449.
11. 1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: observational case control studies. PLoS One. 2013;8(6):e65326.
12. Stride A, Vaxillaire M, Tuomi T, et al. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia. 2002;45(3):427-435.
13. Stride A, Shields B, Gill-Carey O, et al. Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia. 2013;(Oct):4.
14. Page RC, Hattersley AT, Levy JC, et al. Clinical characteristics of subjects with amissense mutation in glucokinase. Diabet Med. 1995;12(3):209-217.
15. Velho G, Blanché H, Vaxillaire M, et al. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia. 1997;40(2):217-224.
16. Physicians RCo. Chronic kidney disease in adults: UK guidelines for identification, management and referral. http://www.renal.org/ckdguide/full/ ukckdfull.pdf. Accessed December 6, 2013.
17. UK National Screening Committee. Essential elements in developing a diabetic retinopathy screening programme. http://www.rcophth.ac.uk/core/core- picker/download.asp?id=552. Accessed December 6, 2013.
18. Criqui MH, Denenberg JO, Bird CE, Fronek A, Klauber MR, Langer RD. The correlation between symptoms and noninvasive test results in patients referred for peripheral arterial disease testing. Vasc Med. 1996;1(1):65-71.
19. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ. 1962;27:645-658.
20. Prineas RJ, Crow RS, Zhang Z-M. The Minnesota Code Manual of Electrocardiographic Findings. Bristol, England: John Wright; 1982.
21. Horn PS, Feng L, Li Y, Pesce AJ. Effect of outliers and nonhealthy individuals on reference interval estimation. Clin Chem. 2001;47(12):2137-2145.
22. Velho G, Vaxillaire M, Boccio V, Charpentier G, Froguel P. Diabetes complications in NIDDM kindreds linked to the MODY3 locus on chromosome 12q. Diabetes Care. 1996;19(9):915-919.
23. Hillege HL, Janssen WM, Bak AA, et al; Prevend Study Group. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med. 2001;249(6):519-526.
24. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in nondiabetic subjects. Islington Diabetes Survey. Lancet. 1988;2(8610):530-533.
25. Klein R, Klein BE, Moss SE, Wong TY. The relationship of retinopathy in persons without diabetes to the 15-year incidence of diabetes and hypertension: Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2006;104:98-107.
26. Gregg EW, Gu Q, Williams D, et al. Prevalence of lower extremity diseases associated with normal glucose levels, impaired fasting glucose, and diabetes among US adults aged 40 or older. Diabetes Res Clin Pract. 2007;77(3):485-488.
27. Gregg EW, Sorlie P, Paulose-Ram R, et al; 1999-2000 national health and nutrition examination survey. Prevalence of lower-extremity disease in the US adult population ≥40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care. 2004;27(7):1591-1597.
28. van Leiden HA, Dekker JM, Moll AC, et al. Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study. Diabetes Care. 2002;25(8):1320-1325.
29. Byrne MM, Sturis J, Menzel S, et al. Altered insulin secretory responses to glucose in diabetic and nondiabetic subjects with mutations in the diabetes susceptibility gene MODY3 on chromosome 12. Diabetes. 1996;45(11):1503-1510.
30. Khaw KT, Wareham N. Glycated hemoglobin as a marker of cardiovascular risk. Curr Opin Lipidol. 2006;17(6):637-643.
31. UKPDS SG. UK Prospective Diabetes Study 6. UK Prospective Diabetes Study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res. 1990;13(1):1-11.
32. Townsend N, Wickramasinghe K, Bhatnagar P, et al. Coronary Heart Disease Statistics 2012 Edition. London, England: British Heart Foundation; 2012.